Coherus Oncology (CHRS) Cash & Current Investments (2013 - 2026)

Coherus Oncology has reported Cash & Current Investments for 14 years, with the latest figure at $167.0 million in Q1 2026.

• Quarterly Cash & Current Investments rose 102.7% year-over-year to $167.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $167.0 million (up 102.7% YoY) and the FY2025 annual result came in at $172.1 million, up 36.62% from the prior year.
• Cash & Current Investments fell to $167.0 million in Q1 2026 per CHRS's latest filing, from $172.1 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $325.7 million in Q1 2022 and troughed at $82.4 million in Q1 2025.
• A 5-year average of $182.1 million and a median of $167.0 million in 2026 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2024 and 2025: Cash & Current Investments surged 102.81% in 2024, then tumbled 68.28% in 2025.
• Over 5 years, Cash & Current Investments stood at $191.7 million in 2022, then slumped by 38.57% to $117.7 million in 2023, then climbed by 7.0% to $126.0 million in 2024, then jumped by 36.62% to $172.1 million in 2025, then slipped by 2.95% to $167.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $167.0 million, $172.1 million, and $191.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.